Lantheus Holdings, Inc. $LNTH Shares Sold by Keybank National Association OH

Keybank National Association OH lowered its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 47.7% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 22,800 shares of the medical equipment provider’s stock after selling 20,831 shares during the period. Keybank National Association OH’s holdings in Lantheus were worth $1,729,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of LNTH. M&T Bank Corp bought a new stake in Lantheus in the fourth quarter worth about $370,950,000. Farallon Capital Management LLC boosted its position in shares of Lantheus by 56.1% during the 4th quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock valued at $361,199,000 after purchasing an additional 1,950,252 shares in the last quarter. Reinhart Partners LLC. boosted its position in shares of Lantheus by 15.9% during the 4th quarter. Reinhart Partners LLC. now owns 1,562,576 shares of the medical equipment provider’s stock valued at $103,990,000 after purchasing an additional 214,820 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Lantheus by 3.2% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,415,463 shares of the medical equipment provider’s stock worth $94,202,000 after purchasing an additional 44,374 shares during the last quarter. Finally, Norges Bank acquired a new position in shares of Lantheus in the 4th quarter worth approximately $76,197,000. 99.06% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently weighed in on LNTH shares. Wall Street Zen cut shares of Lantheus from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Weiss Ratings reissued a “hold (c)” rating on shares of Lantheus in a research note on Tuesday, May 26th. The Goldman Sachs Group restated a “neutral” rating and issued a $94.00 target price on shares of Lantheus in a report on Thursday, May 7th. Citizens Jmp reaffirmed a “market outperform” rating and set a $115.00 target price on shares of Lantheus in a research report on Monday, June 29th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Lantheus in a report on Friday, May 8th. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $101.86.

Lantheus Trading Down 1.5%

Lantheus stock traded down $1.51 during midday trading on Tuesday, reaching $101.31. The stock had a trading volume of 193,711 shares, compared to its average volume of 959,031. Lantheus Holdings, Inc. has a twelve month low of $47.25 and a twelve month high of $111.86. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.83 and a quick ratio of 2.64. The firm has a market cap of $6.60 billion, a price-to-earnings ratio of 24.13 and a beta of -0.06. The firm’s fifty day simple moving average is $98.94 and its two-hundred day simple moving average is $81.89.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.25 by $0.21. The company had revenue of $377.33 million during the quarter, compared to analyst estimates of $354.48 million. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The company’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.53 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Equities analysts anticipate that Lantheus Holdings, Inc. will post 4.49 EPS for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.